Preeclampsia Market Summary

• The Preeclampsia Market Size in the 7MM is expected to grow from USD 87 Million in 2025 to USD 116 Million in 2034.
• The Preeclampsia Market is projected to grow at a CAGR of 3.30% by 2034 in leading countries like the US, EU4, UK, and Japan.

Preeclampsia Market Size and Epidemiological Analysis

• The total Preeclampsia Market Size in the 7MM, the United States accounted for the highest market share, i.e., approximately USD 70 million in 2024.
• Preeclampsia is a complex pregnancy disorder characterized by new-onset hypertension and proteinuria after 20 weeks of gestation. It is believed to stem from placental dysfunction, leading to systemic endothelial activation and inflammatory responses that affect maternal circulation. Preeclampsia is more prevalent in first-time mothers, women with a family history of the condition, and those with preexisting health issues such as hypertension or diabetes.
• Diagnosis of preeclampsia is based on routine prenatal screenings measuring blood pressure and urine protein, confirmed with readings of =140/90 mmHg and proteinuria =300 mg in a 24-h urine collection. 
• In May 2023, Thermo Fisher Scientific received FDA clearance for two assays that assess preeclampsia risk by measuring PIGF and sFlt-1 levels. These assays, the first to receive the breakthrough designation, run in 30 min on the BRAHMS KRYPTOR analyzer and can help evaluate the risk of developing severe preeclampsia in hospitalized pregnant individuals within the next 2 weeks.
• The differential diagnosis of preeclampsia includes antiphospholipid antibody syndrome, thrombotic microangiopathies, lupus nephritis, epilepsy or seizure disorder, chronic renal disease, chronic liver disease, gestational hypertension, chronic hypertension, and others.
• According to DelveInsight’s estimates, the total diagnosed incidence cases of preeclampsia in the 7MM were found to be ~334,000 in 2024.
• In the 7MM, the US accounts for the highest incidence cases of preeclampsia in 2024 with ~218,000 cases.
• There is no approved therapies for preeclampsia, delivery is the only cure and management majorly relies on antihypertensive agents, anticonvulsants, and corticosteroids
• Currently emerging space for preeclampsia is not so active, only few companies are developing and they are also in preclinical stage. Recently Comanche biopharma’s CBP-4888 has become active with Fast Track Designation (FTD) for preeclampsia.

Preeclampsia Market Size and Forecasts

• 2025 Preeclampsia Market Size: USD 87 million in 2025
• 2034 Projected Preeclampsia Market Size: USD 116 million in 2034
• Growth Rate (2025-2034): 3.30% CAGR
• Largest Preeclampsia Market: United States

Key Factors Driving the Preeclampsia Market

Increasing Preeclampsia Incidence

In 2023, malignant pleural effusion accounted for approximately 650K diagnosed cases across the leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Driven by a rising cancer burden, poor prognosis, and improved clinical awareness, these numbers are expected to grow, underscoring the urgent need for novel MPE treatments and better diagnostic approaches.

Growing Opportunities in Targeted Preeclampsia Therapies

Current Preeclampsia treatments like methyldopa, labetalol, nifedipine, and hydralazine effectively manage hypertension and symptoms. The absence of approved therapies addressing the root placental dysfunction presents significant opportunities for innovation and development, driving preeclampsia market growth and encouraging the pursuit of breakthrough targeted treatments.

Untapped Opportunity in Preeclampsia Treatment Market

With no approved therapies currently available, the preeclampsia treatment landscape presents a significant untapped opportunity. Comanche Biopharma’s CBP‑4888 has emerged as a strong contender, recently entering clinical trials and receiving both FDA Fast Track Designation and EMA Orphan Drug Designation, positioning it as a potential first-to-market therapy. With limited competition and rising regulatory support, CBP‑4888 could become the first approved treatment for preeclampsia and a dominant player in this underserved space.

DelveInsight's “Preeclampsia Market Insight, Epidemiology and Market Forecast – 2034” report delivers an in-depth analysis of Preeclampsia epidemiology, market, and clinical development understanding, Addition to this report provides historical and forecasted epidemiology and market data as well as a detailed analysis on the Preeclampsia therapeutics market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The Preeclampsia Market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Preeclampsia Market Size from 2020 to 2034. The report also covers Preeclampsia treatment practices and unmet medical needs to curate the best opportunities and assess the market’s potential

Preeclampsia Disease Understanding

Preeclampsia Overview

Hypertensive disorders of pregnancy constitute a leading cause of maternal and perinatal mortality worldwide. Preeclampsia, with or without severe features, is a disorder of pregnancy associated with new-onset hypertension, usually with accompanying proteinuria, which occurs most often after 20 weeks of gestation and frequently near term. This disease represents a spectrum of hypertensive disease in pregnancy, beginning with gestational hypertension and progressing to develop severe features, ultimately leading to its more severe manifestations, such as eclampsia and HELLP (hemolysis, elevated liver enzymes, low platelet count) syndrome. Early diagnosis and prompt management are essential to preventing both maternal and neonatal complications through symptomatic management and delivery planning.

Further details are provided in the report…

Preeclampsia Diagnosis

Preeclampsia is diagnosed based on the presence of hypertension (systolic BP = 140 mmHg or diastolic BP = 90 mmHg) after 20 weeks of gestation, along with proteinuria (= 300 mg/24 hours or a protein-to-creatinine ratio = 0.3). In the absence of proteinuria, it can still be diagnosed if there are signs of organ dysfunction, such as renal impairment (creatinine > 1.1 mg/dL), elevated liver enzymes, neurological symptoms (e.g., headache, visual disturbances), or thrombocytopenia. Severe preeclampsia is characterized by significantly elevated BP (= 160/110 mmHg), marked proteinuria, or complications like pulmonary edema and organ damage. 

Further details related to country-based variations are provided in the report…

Preeclampsia Treatment

To manage high blood pressure, medications like labetalol, nifedipine, or methyldopa may be prescribed. Labetalol is specifically licensed for pregnant women, while the others are used off-label when the benefits outweigh the risks. In severe cases, anticonvulsant medicine may be given to prevent or treat fits. Delivery is typically recommended around the 37th to 38th week, either through induced labor or cesarean section, to minimize complications. If the condition worsens before 37 weeks, earlier delivery may be necessary. Premature birth may pose additional risks for the baby. After delivery, preeclampsia generally improves, but complications can develop in the days following birth. Blood pressure will continue to be monitored, and additional medication may be prescribed if necessary. The baby may require monitoring in a neonatal intensive care unit if born prematurely. Postpartum, the patient will have follow-up appointments to check blood pressure and assess whether ongoing treatment is needed. 

Further details related to treatment and management are provided in the report…

Preeclampsia Epidemiology

The Preeclampsia epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Incidence Cases, Total Diagnosed Incidence Cases, Age-specific Cases, Sub-type specific Cases, Severity specific Cases, Treated Cases of Preeclampsia in the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034. 

Key Findings from the Preeclampsia Epidemiological Analyses and Forecasts

• According to DelveInsight’s estimates, the total diagnosed incidence cases of preeclampsia in the 7MM were found to be ~334,000 in 2024.
• The US accounted for ~220,000 diagnosed incidence cases of Preeclampsia in 2024.
• Among the age-specific cases, 25-29 yrs comprised ~66,000 cases, whereas 30-34 years comprised ~63,000 cases of preeclampsia in the US in 2024.
• Among EU4 and the UK, Germany had the highest diagnosed incidence population of preeclampsia with ~26,000 cases, followed by France, which had ~25,000 cases in 2024. 
• In 2024, the US reported the highest number of late-onset cases and early-onset cases, with ~260,000 and ~30,000 cases, respectively.

Preeclampsia Epidemiology Segmentation

• Preeclampsia Incidence Cases
• Preeclampsia Diagnosed Incidence Cases
• Preeclampsia Age-specific Cases
• Preeclampsia Sub-type Specific Cases
• Preeclampsia Treated Cases

Preeclampsia Drug Analysis

The section dedicated to drugs in the Preeclampsia report provides an in-depth evaluation of pipeline drugs related to Preeclampsia. The drug chapters section provides valuable information on various aspects related to clinical trials of Preeclampsia, such as the pharmacological mechanisms of the drugs involved, designations, approval status, patent information, and a comprehensive analysis of the pros and cons associated with each drug. Furthermore, it presents the most recent news updates and press releases on drugs targeting Preeclampsia.

Preeclampsia Market Outlook

Currently, there are no effective pharmacological treatments or preventive strategies for preeclampsia. Available therapies primarily focus on controlling hypertension, a secondary consequence of placental dysfunction, rather than addressing the underlying pathophysiology. The optimal management strategy hinges on gestational age and disease severity, balancing maternal safety with fetal viability. As delivery remains the only definitive cure, clinicians must carefully time interventions to minimize risks while ensuring fetal maturation. 

Aspirin is the most widely used preventive measure, with evidence suggesting that early initiation before 16 weeks of gestation may mitigate the risk of preeclampsia. However, its efficacy is significantly diminished when started later, underscoring the importance of early risk stratification and intervention.

• A few key players are leading the Preeclampsia treatment landscape, such as Comanche Biopharma, and others. The details of the country-wise and therapy-wise market size have been provided below.
• In the total market size of Preeclampsia in the 7MM, the United States accounted for the highest market share, i.e. approximately USD 70 million in 2024.
• In 2024, Germany and France generated the highest revenue among the EU4 and the UK, reaching nearly USD 4 million.
• There is no approved therapies for preeclampsia, delivery is the only cure and management majorly relies on antihypertensive agents, anticonvulsants, and corticosteroids.
• Antihypertensive therapy remains the cornerstone of preeclampsia management. In 2024, antihypertensive agents accounted for ~USD 50 million of the US market valuation.

Preeclampsia Drugs Uptake

This section focuses on the uptake rate of potential Preeclampsia drugs expected to be launched in the market during 2020–2034, which depends on the competitive landscape, safety, efficacy data along with order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.

Preeclampsia Clinical Trials Analysis

The Preeclampsia market report provides insights into Preeclampsia clinical trials within the Phase III and Phase II stages. It also analyzes key players involved in developing targeted therapeutics.

Preeclampsia Pipeline Development Activities

The Preeclampsia market report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Preeclampsia emerging therapies.

Latest KOL Views on Preeclampsia

To stay abreast of the latest trends in the market, we conduct primary research by seeking the opinions of Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) who work in the relevant field. This helps us fill any gaps in data and validate our secondary research. We have reached out to industry experts to gather insights on various aspects of Preeclampsia, including the evolving treatment landscape, patients’ reliance on conventional therapies, their acceptance of therapy switching, drug uptake, and challenges related to accessibility. The experts we contacted included medical/scientific writers, professors, and researchers from prestigious universities in the US, Europe, the UK, and Japan.

Our team of analysts at Delveinsight connected with more than 10 KOLs across the 7MM. We contacted institutions such as the National Institute of Child Health and Human Development, St. Joseph's Health Care, University of Milan, Nagoya City University, etc., among others. By obtaining the opinions of these experts, we gained a better understanding of the current and emerging treatment patterns in the Preeclampsia market, which will assist our clients in analyzing the overall epidemiology and market scenario. 

Preeclampsia Report Qualitative Analysis

We perform Qualitative and Market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst’s discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, designation, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy. Further, the therapies’ safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided. 

Preeclampsia Market Access and Reimbursement

Because newly authorized drugs are often expensive, some patients escape receiving proper treatment or use off-label, less expensive prescriptions. Reimbursement plays a critical role in how innovative treatments can enter the market. The cost of the medicine, compared to the benefit it provides to patients who are being treated, sometimes determines whether or not it will be reimbursed. Regulatory status, target population size, the setting of treatment, unmet needs, the number of incremental benefit claims, and prices can all affect market access and reimbursement possibilities.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Preeclampsia Market Report Insights

• Preeclampsia Patient Population
• Preeclampsia Therapeutic Approaches
• Preeclampsia Market Size and Trends
• Existing Market Opportunity 
• Preeclampsia Drug Market
• Preeclampsia Emerging Drugs

Preeclampsia Market Report Key Strengths

• 10-year Forecast
• The 7MM Coverage 
• Preeclampsia Epidemiology Segmentation
• Key Cross Competition 
• Preeclampsia Drugs Uptake

Preeclampsia Market Report Assessment

• Current Preeclampsia Treatment Practices
• Preeclampsia Market Reimbursements
• Preeclampsia Market Attractiveness
• Qualitative Analysis (SWOT, Conjoint Analysis, Unmet needs)
• Preeclampsia Market Drivers
• Preeclampsia Market Barriers

Key Questions Answered In The Preeclampsia Market Forecast Report

Preeclampsia Market Insights

• Would there be any changes observed in the current treatment approach?
• Will there be any improvements in Preeclampsia management recommendations?
• Would research and development advances pave the way for future tests and therapies for Preeclampsia?
• Would the diagnostic testing space experience a significant impact and lead to a positive shift in the treatment landscape of Preeclampsia?
• What kind of uptake will the new therapies witness in the coming years in Preeclampsia patients?